ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL

December 3-6, 2016; San Diego, California
Phase II trial suggests durable, MRD-negative CR in 82% of patients after infusion of CTL019 CAR T-cells.
Format: Microsoft PowerPoint (.ppt)
File Size: 477 KB
Released: December 9, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

In this short summary slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

person default Mansoor Raza Mirza, MD Bradley J. Monk, MD, FACS, FACOG Prof Isabelle Ray Coquard Released: March 8, 2021

Jorge Cortes, MD, and Eunice S. Wang, MD, discuss their top presentation choices at ASH 2020 in acute and chronic leukemias with the greatest potential to impact clinical practice

Jorge Cortes, MD Eunice S. Wang, MD Released: March 3, 2021

In this slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

person default Mansoor Raza Mirza, MD Bradley J. Monk, MD, FACS, FACOG Prof Isabelle Ray Coquard Released: March 2, 2021

Interactive online tool providing expert treatment recommendations for newly diagnosed and relapsed/refractory follicular lymphoma from CCO

John M. Burke, MD Ian W. Flinn, MD, PhD Christopher R. Flowers, MD, MS John P. Leonard, MD Jeff P. Sharman, MD Released: March 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue